Should expensive drugs be offered free of charge - either on the NHS or by private medical insurers? Johanna Gornitzki takes a closer look at the Herceptin debate
In 2005, Health Secretary Patricia Hewitt said no patient diagnosed with early stage breast cancer should be denied access to Herceptin on the grounds of cost. This caused lobbyists throughout the UK to breath a sigh of relief, thinking the battle had been won. But this was not the case - as cancer sufferer Ann Marie Rogers found out in February this year when she lost her legal case to receive Herceptin on the NHS. Her situation reignited the debate over whether all patients diagnosed with early stage breast cancer should have the right to receive the drug for free. However, with tho...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes